BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 22034865)

  • 1. Targeting metastatic melanoma.
    Flaherty KT
    Annu Rev Med; 2012; 63():171-83. PubMed ID: 22034865
    [TBL] [Abstract][Full Text] [Related]  

  • 2. BRAF, a target in melanoma: implications for solid tumor drug development.
    Flaherty KT; McArthur G
    Cancer; 2010 Nov; 116(21):4902-13. PubMed ID: 20629085
    [TBL] [Abstract][Full Text] [Related]  

  • 3. BRAF inhibitors: research accelerates in wake of positive findings.
    Brower V
    J Natl Cancer Inst; 2010 Feb; 102(4):214-5. PubMed ID: 20145213
    [No Abstract]   [Full Text] [Related]  

  • 4. Role of the MEK inhibitor trametinib in the treatment of metastatic melanoma.
    King JW; Nathan PD
    Future Oncol; 2014; 10(9):1559-70. PubMed ID: 25145427
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New drug targets in metastatic melanoma.
    Homet B; Ribas A
    J Pathol; 2014 Jan; 232(2):134-41. PubMed ID: 24027077
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Selective blockade of the mutated BRAF leads to a survival benefit in patients with metastatic melanoma].
    Schadendorf D
    J Dtsch Dermatol Ges; 2011 Apr; 9(4):340. PubMed ID: 21439018
    [No Abstract]   [Full Text] [Related]  

  • 7. A new standard of care for metastatic melanoma?
    Sharma SP
    Lancet Oncol; 2015 Jan; 16(1):e8. PubMed ID: 25638559
    [No Abstract]   [Full Text] [Related]  

  • 8. Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma.
    Long GV; Menzies AM; Nagrial AM; Haydu LE; Hamilton AL; Mann GJ; Hughes TM; Thompson JF; Scolyer RA; Kefford RF
    J Clin Oncol; 2011 Apr; 29(10):1239-46. PubMed ID: 21343559
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Is it good or bad to find a BRAF mutation?
    Flaherty KT
    J Clin Oncol; 2011 Apr; 29(10):1229-30. PubMed ID: 21343552
    [No Abstract]   [Full Text] [Related]  

  • 10. Changes in tumor morphology and cyclin-dependent kinase inhibitor expression in metastatic melanoma treated with selective second-generation BRAF inhibitor.
    Curry JL; Falchook GS; Hwu WJ; Torres-Cabala CA; Duvic M; Tetzlaff MT; Prieto VG
    Am J Dermatopathol; 2013 Feb; 35(1):125-8. PubMed ID: 22878367
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeted therapy for melanoma: rational combinatorial approaches.
    Kwong LN; Davies MA
    Oncogene; 2014 Jan; 33(1):1-9. PubMed ID: 23416974
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting mutant BRAF and KIT in metastatic melanoma: ASCO 2009 meeting report.
    Sondak VK; Smalley K
    Pigment Cell Melanoma Res; 2009 Aug; 22(4):386-7. PubMed ID: 19624312
    [No Abstract]   [Full Text] [Related]  

  • 13. Intermittent BRAF-inhibitor therapy is a feasible option: report of a patient with metastatic melanoma.
    Koop A; Satzger I; Alter M; Kapp A; Hauschild A; Gutzmer R
    Br J Dermatol; 2014 Jan; 170(1):220-2. PubMed ID: 24032672
    [No Abstract]   [Full Text] [Related]  

  • 14. [Understanding current therapies in metastatic melanoma].
    Rodríguez R; Parra A; González S; Molgó M; Droppelmann N; Acevedo F; Peña J; Uribe P
    Rev Med Chil; 2016 Nov; 144(11):1448-1458. PubMed ID: 28394962
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel inhibitors in the treatment of metastatic melanoma.
    Kalinsky K; Haluska FG
    Expert Rev Anticancer Ther; 2007 May; 7(5):715-24. PubMed ID: 17492934
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [BRAF mutation testing for the choice of melanoma treatment].
    Imianitov EN
    Arkh Patol; 2012; 74(5):65-71. PubMed ID: 23342664
    [TBL] [Abstract][Full Text] [Related]  

  • 17. BRAF-Targeted Therapy to Treat Superior Vena Cava Syndrome in a Patient With Metastatic Cancer.
    Mesko SM; Rosenthal KJ; Boasberg PD; Hamid O
    J Clin Oncol; 2015 Sep; 33(25):e101-3. PubMed ID: 24711550
    [No Abstract]   [Full Text] [Related]  

  • 18. Oncogenetics of melanoma: basis for molecular diagnostics and therapy.
    Held L; Eigentler TK; Meier F; Held M; Röcken M; Garbe C; Bauer J
    J Dtsch Dermatol Ges; 2011 Jul; 9(7):510-6. PubMed ID: 21244632
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting oncogenic drivers and the immune system in melanoma.
    McArthur GA; Ribas A
    J Clin Oncol; 2013 Feb; 31(4):499-506. PubMed ID: 23248252
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Melanoma and search for therapeutic targets].
    de la Fouchardière A
    Ann Pathol; 2011 Nov; 31(5 Suppl):S123-4. PubMed ID: 22054449
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 13.